TrialCancer research and treatment2016

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL).

Keunchil Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.